Ovarian Cancer: Current Scenario, Treatment And Novel Strategies For Management
Ovarian cancer is the leading gynaecological cancer among women globally and leads to death with 5-year survival rate of metastatic form of ovarian cancer as only 20-30%. Detection of disease at an early stage is very difficult and no screening test are available for detection of OC in general population. For effective management of ovarian cancer chemotherapy, surgery, hormone therapy and radiation therapy are often used alone or in combination depending on the stage and severity of ovarian cancer. This mini-review describes about facts and figures as well as current diagnosis and treatment methods available for ovarian cancer. The manuscript will also cover a brief description of recent research of developing novel strategies such as liposomal drug delivery carriers in management of cancer.
2. Kuhn E, Kurman RJ, Shih IM. Ovarian Cancer Is an Imported Disease: Fact or Fiction? Current obstetrics and gynecology reports. 2012;1(1):1-9.
3. Kurman RJ, Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 2008;27(2):151-60.
4. Fagotti A, Fanfani F, Vizzielli G, Gallotta V, Ercoli A, Paglia A, et al. Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery? Gynecologic oncology. 2010;116(1):72-7.
5. Bhatt P, Vhora I, Patil S, Amrutiya J, Bhattacharya C, Misra A, et al. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. J Control Release. 2016;226:148-67.
6. Berek J. Ch. 11 Ovarian Cancer. In: Berek JS HN, editor. Practical Gynecologic Oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 443-511.
7. Zhi D, Zhang S, Cui S, Zhao Y, Wang Y, Zhao D. The Headgroup Evolution of Cationic Lipids for Gene Delivery. Bioconjugate Chemistry. 2013;24(4):487-519.
8. Bhatt P, Narvekar P, Lalani R, Chougule MB, Pathak Y, Sutariya V. An in vitro Assessment of Thermo-Reversible Gel Formulation Containing Sunitinib Nanoparticles for Neovascular Age-Related Macular Degeneration. AAPS PharmSciTech. 2019;20(7):281.
9. Kolate A, Baradia D, Patil S, Vhora I, Kore G, Misra A. PEG - a versatile conjugating ligand for drugs and drug delivery systems. Journal of controlled release : official journal of the Controlled Release Society. 2014;192:67-81.
10. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 – an update. The Journal of Gene Medicine. 2013;15(2):65-77.
11. Dos Santos N, Allen C, Doppen A-M, Anantha M, Cox KAK, Gallagher RC, et al. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation lifetimes to protein binding. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2007;1768(6):1367-77.
12. Naldini L. Gene therapy returns to centre stage. Nature. 2015;526(7573):351-60.
13. Patel J, Amrutiya J, Bhatt P, Javia A, Jain M, Misra A. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. J Microencapsul. 2018;35(2):204-17.
14. Basu P, De P, Mandal S, Ray K, Biswas J. Study of 'patterns of care' of ovarian cancer patients in a specialized cancer institute in Kolkata, eastern India. Indian journal of cancer. 2009;46(1):28-33.
15. Husseinzadeh N. Status of tumor markers in epithelial ovarian cancer has there been any progress? A review. Gynecologic oncology. 2011;120(1):152-7.
16. Lalani R, Misra A, Amrutiya J, Patel H, Bhatt P, Patil SK. Approaches and Recent Trends in Gene Delivery for Treatment of Atherosclerosis. Recent Pat Drug Deliv Formul. 2016;10(2):141-55.
17. Marchetti C, Pisano C, Facchini G, Bruni GS, Magazzino FP, Losito S, et al. First-line treatment of advanced ovarian cancer: current research and perspectives. Expert review of anticancer therapy. 2010;10(1):47-60.
18. Patil S, Bhatt P, Lalani R, Amrutiya J, Vhora I, Kolte A, et al. Low molecular weight chitosan–protamine conjugate for siRNA delivery with enhanced stability and transfection efficiency. RSC Advances. 2016;6(112):110951-63.
19. Kean A. The present status of radiation therapy in cancer of the ovaries. The American Journal of Surgery. 1935;27(3):425-9.
20. Lalani R, Misra A, Amrutiya J, Patel H, Bhatt P, Patel V. Challenges in Dermal Delivery of Therapeutic Antimicrobial Protein and Peptides. Curr Drug Metab. 2017;18(5):426-36.
21. Javia A, Amrutiya J, Lalani R, Patel V, Bhatt P, Misra A. Antimicrobial peptide delivery: an emerging therapeutic for the treatment of burn and wounds. Ther Deliv. 2018;9(5):375-86.
22. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. Journal of Molecular Biology. 1965;13(1):238-IN27.
23. Sharma A, Sharma US. Liposomes in drug delivery: Progress and limitations. International Journal of Pharmaceutics. 1997;154(2):123-40.
24. Patil S, Lalani R, Bhatt P, Vhora I, Patel V, Patel H, et al. Hydroxyethyl substituted linear polyethylenimine for safe and efficient delivery of siRNA therapeutics. RSC Advances. 2018;8(62):35461-73.
25. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends in pharmacological sciences. 2009;30(11):592-9.
26. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urologic oncology. 2008;26(1):57-64.
27. Straubinger RM, Hong K, Friend DS, Papahadjopoulos D. Endocytosis of liposomes and intracellular fate of encapsulated molecules: encounter with a low pH compartment after internalization in coated vesicles. Cell. 1983;32(4):1069-79.
28. Bhatt P, Fnu G, Bhatia D, Shahid A, Sutariya V. Nanodelivery of Resveratrol-Loaded PLGA Nanoparticles for Age-Related Macular Degeneration. AAPS PharmSciTech. 2020;21(8):291.
29. Lasic DD. Liposomes: from physics to applications: Elsevier; 1993.
30. Huwyler J, Drewe J, Krähenbühl S. Tumor targeting using liposomal antineoplastic drugs. International Journal of Nanomedicine. 2008;3(1):21-9.
31. Oake A, Bhatt P, Pathak YV. Understanding Surface Characteristics of Nanoparticles. In: Pathak YV, editor. Surface Modification of Nanoparticles for Targeted Drug Delivery. Cham: Springer International Publishing; 2019. p. 1-17.
32. Chang H-I, Yeh M-K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. International Journal of Nanomedicine. 2012;7:49-60.
33. Chou HH, Wang KL, Chen CA, Wei LH, Lai CH, Hsieh CY, et al. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up. Gynecologic oncology. 2006;101(3):423-8.
34. Narvekar P, Bhatt P, Fnu G, Sutariya V. Axitinib-Loaded Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Age-Related Macular Degeneration: Formulation Development and In Vitro Characterization. ASSAY and Drug Development Technologies. 2019;17(4):167-77.
35. Tejada-Berges T, Granai CO, Gordinier M, Gajewski W. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert review of anticancer therapy. 2002;2(2):143-50.
36. Lorusso V, Manzione L, Silvestris N. Role of liposomal anthracyclines in breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2007;18 Suppl 6:vi70-3
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).